---
title: "Ensysce Biosciences surges 77% in regular trading on Cy Biopharma acquisition"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295113680.md"
description: "Ensysce Biosciences rose 77% after completing its Cy Biopharma acquisition for CRPS drug CY200 and releasing investor presentation."
datetime: "2026-08-06T13:37:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295113680.md)
  - [en](https://longbridge.com/en/news/295113680.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295113680.md)
---

# Ensysce Biosciences surges 77% in regular trading on Cy Biopharma acquisition

Ensysce Biosciences(ENSC.US) 盘中急涨，现涨超 76%，现报 0.6406 美元。

公司于今日完成对 Cy Biopharma 的收购，获得临床阶段候选药物 CY200，用于复杂性区域疼痛综合征治疗。该交易包含 1710 万美元现金及同步进行的 2150 万美元定向增发，并设有与临床里程碑挂钩的 3860 万美元后续融资批次。资金将支持 2028 年之前的二期开发及注册准备工作。

此外，Ensysce 发布了投资者演示，重点介绍其胰蛋白酶控制的阿片类药物平台 TAAP 和 MPAR，旨在防止药物滥用。公司指出其 TAAP 羟考酮产品于 2024 年 1 月获 FDA 突破性疗法认定，开发计划包括 2026 年开展 PF614-MPAR 的 1b/3 期研究及 2028 年提交新药申请。

### Related Stocks

- [ENSC.US](https://longbridge.com/en/quote/ENSC.US.md)

## Related News & Research

- [Ensysce Biosciences Q2 net loss widens on higher R&D costs](https://longbridge.com/en/news/295841617.md)
- [Ensysce Biosciences posts investor presentation spotlighting trypsin-controlled opioid platforms, pain pipeline](https://longbridge.com/en/news/295107304.md)
- [Ensysce Biosciences completes Cy Biopharma acquisition](https://longbridge.com/en/news/295106106.md)
- [Ensysce enrolls first patient in final phase of PF614-MPAR-102 overdose-protection trial](https://longbridge.com/en/news/290962389.md)
- [Ensysce Biosciences GAAP EPS of -$0.52 beats by $0.21](https://longbridge.com/en/news/286613093.md)